Advertisement

Topics

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

01:00 EDT 6 Sep 2017 | Labiotech.eu

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy.  I sat down with Gregg Sando of Cell Medica to hear the perspective of a ...

This awesome article The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

NEXT ARTICLE

More From BioPortfolio on "The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue"

Quick Search
Advertisement
 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...